Home Company

About

Genalyte is a health care diagnostics and analytics company that improves patient outcomes and lowers cost by offering real-time laboratory results for physicians and patients. Genalyte delivers rapid, actionable results to doctors through decentralized laboratory testing.

Home Company

Leadership

Our leadership team draws on diverse backgrounds spanning healthcare and technology.

ASHRAF HANNA, MD PHD

ASHRAF HANNA, MD PHD

CEO

Ashraf Hanna is the Chief Executive Officer at Genalyte. 

Ashraf joined Genalyte as Chief Executive Officer from Verily, an Alphabet company, where he was Chief Operating Officer.  Among other activities, he helped lead the company to obtain its first 510k approval and expand Covid testing sites during the pandemic.  Prior to Verily, Ashraf was the CEO at ORIC Pharmaceuticals, a company focused on developing drugs for resistant cancers.   Ashraf led the company from concept through preclinical and the beginning of Phase 1 clinical trials.  ORIC had an IPO at approximately $1B valuation while still in Phase 1.   Ashraf spent over a decade at Genentech as Vice President and head of Alliance Management, Portfolio Prioritization, and head of Commercial and Medical Affairs Finance.  He started his work career at McKinsey and Company.  Ashraf has a PhD in Physics from Harvard, and an M.D. from the University of Massachusetts and studied Physics and Economics as an undergraduate at the University of Chicago.  

Rachel Larrenaga, J.D., Esq.

Rachel Larrenaga, J.D., Esq.

General Counsel

Rachel is responsible for overseeing all legal affairs at Genalyte including commercial transactions, business development transactions, intellectual property, corporate governance, and compliance.  Rachel brings extensive legal experience with over an 18-year career, in commercial negotiations, intellectual property licensing, acquisitions, and venture-backed financing.  

Most recently, Rachel was Vice President of Legal at ChargePoint, one of the leaders in electric vehicle charging. She joined ChargePoint in 2014 as its second legal hire and helped grow the organization thru its recent transition to a public company in March 2021.  She helped build and was most recently responsible for the entire North America commercial team and was responsible for negotiating high risk and high reward contracts.  Before going in-house Rachel worked as a senior associate at Orrick Herrington and Sutcliffe and Murray & Murray. 

Rachel holds a BA from UC Davis (Summa Cum Laude) and a J.D. from UC Hastings (magnum cum laude, Order of the Coif).  Rachel is admitted to both the California and Texas State Bars.

CASIMIR STARSIAK III

CASIMIR STARSIAK III

Sr. VP of Product and Operations

Casimir joined Genalyte from Verily, Google’s healthcare and life sciences spinout. There he wore many hats including building and leading the Strategy and Business Operations team and as General Manager for the Baseline clinical trials platform. Prior to joining Verily, Casimir spent 5 years on Google’s Strategy team leading a variety of projects across the organization. Examples include helping to kickstart Google’s Cloud Genomics product as well as supporting the initial strategy and business planning for the nascent life sciences efforts in Google X, which eventually led to the creation of Verily. Prior to Alphabet, Casimir spent time in McKinsey & Company’s Business Technology practice as well as working at the Indianapolis VA Hospital as an Industrial Engineering Fellow. He received a B.S. from Purdue University in Industrial Engineering and a Masters in Management Science and Engineering from Stanford University.

RICK HOCKETT, MD

RICK HOCKETT, MD

CMO

A clinical pathologist certified by the American Board of Pathology, Chief Medical Officer Rick Hockett is the mind behind Genalyte’s clinical strategy, development and operations.

Dr. Hockett oversees the daily operations of Genalyte’s CLIA laboratory and 510(k) submission of Genalyte’s proprietary diagnostic instrumentation and assays for regulatory approval. Dr. Hockett has spent three decades applying biomarkers to clinical medicine, distinguishing himself as a leader in personalized medicine. Among many professional achievements, Dr. Hockett was responsible for the first standalone genetic component for a New Drug Application to the U.S. Food and Drug Administration. He maintains active medical licenses in Indiana, California, New York and Colorado. Dr. Hockett earned his bachelor’s degree in Chemistry at the University of South Dakota and his Doctorate of Medicine from the University of Minnesota; he completed his residency in Clinical Pathology at Washington University, St. Louis.

MICHAEL O’NEIL

MICHAEL O’NEIL

VP, Product Marketing

Michael leads Genalyte’s strategic direction by reading the market, identifying key market segments and designing innovative products and services to meet those needs.  As part of a twenty year career at Blue Shield of California, Michael spearheaded the design and implementation of one of the first Accountable Care Organizations (ACOs) in the country while serving as Senior Director of Product Innovation. Improving quality of healthcare while cutting costs by almost $38 million in two years for 40K CalPERS members, the ACO model has been replicated by more than 32 medical groups and hospitals across the state.  Michael later became Vice President of Product and Market Alignment at Blue Shield of California where he oversaw product innovation and management for all Commercial offerings including the adoption of and transition to the Affordable Care Act.  Michael earned his bachelor’s degree in Political Science from Dartmouth College and a master’s degree in Education from Stanford University.

SASI MUDUMBA, PHD

SASI MUDUMBA, PHD

VP, Assay Development

Dr. Mudumba oversees the research, development, validation, regulatory submission and approval of the diagnostic assays at the heart of Genalyte’s revolutionary technology.

Dr. Mudumba has spent more than 20 years in research, development and commercialization in the life sciences, pharmaceutical and medical device industries. Dr. Mudumba has guided several In Vitro Diagnostics (IVD) products through approvals at federal agencies including the Food and Drug Administration and Health Canada, and was responsible for leading a multiplexed autoimmune IVD assay on microarray technology from development to regulatory approval. Her previous roles include Director of Assay Development of Regulatory Affairs at SQI Diagnostics and Senior Scientist at NoAb BioDiscoveries. Dr. Mudumba earned her bachelor’s degree in Microbiology at Osmania University before obtaining her master’s degree in Biochemistry from the University of Hyderabad; her PhD in Biotechnology is from Jawaharlal Nehru Technological University.

Jessica Silvestre, PHD

Jessica Silvestre, PHD

Head of Quality

As Head of Quality, Jessica’s focus is to provide medical devices and related services that consistently meet customer and applicable regulatory requirements. She previously served as Head of Quality for Boston Scientific, developing and manufacturing implantable neurostimulators to help patients with chronic pain and movement disorders such as Parkinson’s Disease.  During her 13 years at Boston Scientific, Jessica was involved in multiple projects for Class III active implantable medical devices, from concept through 510(k) and PMA approvals, first patient implant, and beyond to post-market surveillance.  She also oversaw multi-million dollar production transfers and acquisition integrations.

Jessica earned her bachelor’s degree in Biological and Environmental Engineering from Cornell University and her PhD in Biomedical Engineering from the University of Southern California.  Her doctoral research in orthopaedic biomechanics resulted in multiple peer-reviewed publications in journals, most notably on wear of metal-on-metal artificial discs for the lumbar spine.

Jessica’s passion for helping others is reflected in her 7 years of service as a Search and Rescue volunteer, which required training and certification as an Emergency Medical Technician (EMT), Mountain Rescue Technician, and Sheriff’s Deputy.

Board of Directors

ASHRAF HANNA

CEO

Ashraf Hanna is the Chief Executive Officer of Genalyte. 

Ashraf joined Genalyte as Chief Executive Officer from Verily, an Alphabet company, where he was Chief Operating Officer.  Among other activities, he helped lead the company to obtain its first 510k approval and expand Covid testing sites during the pandemic.  Prior to Verily, Ashraf was the CEO at ORIC Pharmaceuticals, a company focused on developing drugs for resistant cancers.   Ashraf led the company from concept through preclinical and the beginning of Phase 1 clinical trials.  ORIC had an IPO at approximately $1B valuation while still in Phase 1.   Ashraf spent over a decade at Genentech as Vice President and head of Alliance Management, Portfolio Prioritization, and head of Commercial and Medical Affairs Finance.  He started his work career at McKinsey and Company.  Ashraf has a PhD in Physics from Harvard, and an M.D. from the University of Massachusetts and studied Physics and Economics as an undergraduate at the University of Chicago.  

CARY GUNN

Member, Board of Directors

Dr. Cary Gunn has been blazing trails in the technology community for almost 30 years.

Prior to founding Genalyte, Cary served as co-founder and Chief Technical Officer of Luxtera, a developer of innovative optical solutions; his military career includes almost 10 years in the United States Air Force, where he was responsible for launching GPS satellites. Holding 81 (and counting) issued U.S. patents, Cary has been recognized in publications including the MIT Technology Review, which named him a Top Young Innovator in 2003. Five years later, Cary’s achievements in silicon photonics were awarded with the Optical Society of America Adolph Lomb Medal and the Berthold-Leibinger Foundation Innovation Prize. He received his bachelor’s degree in Applied Physics and Organic Chemistry from the United States Air Force Academy and his PhD in Electrical Engineering from the California Institute of Technology (Caltech).

SAEID AKHTARI

Member, Board of Directors

Saeid is the Managing Director at HBM Genomics investing in world-class entrepreneurs in life sciences companies.

He has more than 25 years of experience as an entrepreneur building successful biotech companies from scratch. Saeid is an active investor/advisor in leading life sciences companies, including Genalyte, Clear Labs, Convergent Genomics, Encoded Therapeutics, Haystack Biosciences, Seer Biosciences, Trace Genomics, and Xcell Biosciences.

Prior to HBM Genomics, Saeid was the founder, President & CEO of NextBio which was acquired by Illumina in 2013. Prior to founding NextBio, he was the President & CEO of Silicon Genetics which was acquired by Agilent in 2004. Mr. Akhtari has also held executive management positions at several other life sciences companies.

ANDREW CONRAD

Member, Board of Directors

Andrew Conrad, PhD, is the Chief Executive Officer, Chairman and Founder of Verily where he oversees an integrated team of engineers, scientists, designers, and medical experts working on a wide spectrum of healthcare-related projects.
Previously, he was Chief Scientific Officer of Laboratory Corporation of America (LabCorp). Dr. Conrad co-founded the National Genetics Institute, where he served as Chief Scientific Officer. He is a Working Group Member on the Precision Medicine Initiative and a member of the UCSF-Stanford Center of Excellence in Regulatory Science and Innovation (CERSI) Scientific Advisory Board.

JEFF HUBER

Member, Board of Directors

Jeff Huber is the Founding CEO and Vice Chairman of GRAIL (2016-present). GRAIL’s mission is to detect cancer early, when it can be cured.

Prior to GRAIL, Jeff was a Senior Vice President at Google. Over 13 years at Google, Jeff co-founded Google’s life sciences efforts in Google[x] (2013-2016), and led development and scaling for Google Maps (2011-2013), Google Apps (2005-2010), and Google Ads (2003-2011). During his tenure as an executive at Google, Jeff oversaw 50x growth in revenues (from $1 billion to >$50 billion) and organization (1,000 to >50,000 employees), and managed a $5 billion P&L and large distributed teams (5,000+ direct-line employees). Earlier, Jeff was vice president of architecture and systems development at eBay and senior vice president of engineering at Excite@Home, where he led consumer product and infrastructure development.

Jeff was recognized as one of the ‘100 Most Intriguing Entrepreneurs’ (2017), and is an active early-stage investor/advisor in breakthrough life sciences and technology, including Openwater, Mammoth Biosciences, Vir, Sana, Zymergen, Atomwise, Genalyte, Pinterest, Honor, OpenDoor, and AngelList.

Jeff holds a bachelor’s degree in computer engineering from the University of Illinois, where he was Commencement Speaker (2016) and received a ‘Distinguished Alumni Award’ from the College of Electrical & Computer Engineering (2018) for ‘challenging the status quo through innovation’. He also holds a master’s degree in business from Harvard University. Jeff is a board member of GRAIL (Vice Chairman), Genalyte (Chairman), Electronic Arts (EA), Openwater, and The Exploratorium, and a former board member of Illumina (ILMN; 2014-2016).

JOE MARKEE

Member, Board of Directors

Joe Markee Managing Director at Express Ventures

Joe brings extensive experience in early stage company formation, capital raising, corporate management, and public and private corporate governance. Joe’s startup experience encompasses Primary Access as a founder and senior manager, Copper Mountain Networks as founding CEO, CTO and Chairman, Figure 8 Wireless as CEO and StackIQ as CEO and Chairman.

Joe was also a founder and served as President of the San Diego Telecommunications Council (renamed CommNexus). He has been honored with awards for his contributions to San Diego’s high-tech business community, including Master Entrepreneur.

GERARD VAN HAMEL PLATERINK

Member, Board of Directors

Gerard joined Redmile as a managing director in May 2012.

Prior to working with Redmile, Gerard was a Managing Director with Accuitive Medical Ventures (AMV). AMV II has recently been ranked in the top quartile of healthcare VC funds for its vintage year (Source: Cambridge Assoc.). Gerard has cofounded a number of healthcare companies including Halscion, Sebacia and First Aid Shot Therapeutics. In addition, Gerard led AMV’s investments in Axogen (public: AXGN), Cardiofocus, Neuronetics and Intuity Medical. Before AMV, Gerard worked with Novoste Corporation, the cardiology technology company, in business development and corporate communications. Before joining Novoste, Gerard was an equity research analyst with Salomon Brothers (now Citigroup) in London, where he was a member of the top ranked European healthcare research team. Gerard began his career with Kleinwort Benson, where he was an investment banker and member of the bank’s private equity and mezzanine finance group. Gerard is a Dutch national, was born in Borneo in Southeast Asia, grew up in Africa and was educated in the UK where he got his BS in Physics (1st Class Honors) from St. Andrews University and an MBA from Cambridge University.

RAJESH SWAMINATHAN

Member, Board of Directors

Rajesh is a Partner at Khosla Ventures. Rajesh brings with him two decades of experience assisting and investing in deeptech/ hardware startups across many industries including Cleantech and Healthcare.
Before joining Khosla Ventures, Rajesh served as the Head of Applied Ventures LLC, the Venture Capital arm of Applied Materials, where he managed a portfolio of over 85 hardware startups across 13 countries. Rajesh also drove the establishment of an $850M Materials Engineering Technology Accelerator (META) facility in NY, to enable access of semiconductor fabs for startups. Rajesh received Global Corporate Venturing’s (GCV) Powerlist award in 2019.

Before joining Applied Ventures, Rajesh worked at the venture arm of Third Point LLC. Previously, at Lucent’s Bell Labs, he drove the technical assessment & partnerships with several Photonics, MEMS and RF startups. Rajesh also led the design for reliability program for Lucent’s 10Gb/s and 40Gb/s telecommunication systems and supported the successful deployment of these systems globally.

While pursuing his MBA at Harvard Business School, Rajesh interned at Deutsche Bank’s cleantech investment banking group. Rajesh completed his M.S. at the University of Maryland at College Park, and received his Bachelor’s degree in Chemical Engineering from IIT Madras where he was awarded the Shankar Dayal Sharma (President of India) Medal for overall excellence.

Investors